DeutschNewstral
Article
Fft.com on 2024-04-30 14:06
Eli Lilly lifts guidance on strong sales of diabetes and weight loss drugs
Related news
Weight loss, diabetes drugs propel Eli Lilly to better-than-expected forecast for 2024Seattle Times- MEli Lilly beats earnings expectations, raises guidancemarketwatch.com
Eli Lilly & Co: Eli Lilly weight-loss drug found to address sleep apnoea in trialFinancial Times- Eli Lilly & Co: Eli Lilly to seek obesity drug approval that could disrupt weight loss marketFinancial Times
Eli Lilly: Why Earnings Guidance Takes a Back Seatwsj.com
Eli Lilly weight loss drug Zepbound approved by the FDANew York Post- DEli Lilly slumps after disappointing Zepbound weight-loss-drug trialdcourier.com
- MEli Lilly weight reduction drug tirzepatide knowledge launchedmvtelegraph.com
- FEli Lilly & Co: Eli Lilly races to boost capacity for rival to Novo Nordisk weight-loss drugft.com
- BEli Lilly Stock Falls as Sales Disappoint. Analyst Welcomes Diabetes Data.barrons.com
- WEli Lilly returns to RTP with $470M plant for diabetes drugswraltechwire.com
Eli Lilly to cut insulin prices, cap costs at $35 for many people with diabetesSan Jose Mercury News- MEli Lilly slashes guidance in face of pricing pressures and growing generic competitionmarketwatch.com
Fast-growing Cambridge biotech Sigilon inks $63M diabetes deal with Eli Lillybizjournals.com- MEli Lilly CEO on slicing tips, potential weight problems drug, Alzheimer’s trialmvtelegraph.com
- IEli Lilly in ‘good dialogue’ with Germany on weight-loss drug coverageinvezz.com
Sleep apnea reduced in people who took weight-loss drug, Eli Lilly reportsThe New York Times- FEli Lilly says obesity drug’s results compare to weight-loss surgeryft.com
Tesla Now Worth $110 Billion Less Than Weight Loss Drug Maker Eli LillyForbes- DAnalyst revamps Eli Lilly stock price target on weight loss drugdcourier.com